Loading
YAP1 (Transcriptional coactivator YAP1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Breast cancer.
Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signalling pathway, crucial for organ size control and tumour suppression by restricting proliferation and promoting apoptosis. The Hippo signalling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1.
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Docetaxel, Verteporfin and Fluorouracil. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes affected pathway 0.27, literature 1.00, genetic association 0.00, somatic mutation 0.97, animal model 0.53).
In plain words · YAP1 (Transcriptional coactivator YAP1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Breast cancer.
YAP1 (Transcriptional coactivator YAP1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Breast cancer.
Transcriptional regulator with dual roles as a coactivator and corepressor.
No product in this corpus aims at YAP1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA YAP1: RNA low tissue specificity; high antibody staining in 1 normal tissue; highest cancer staining cervical cancer (2 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Oesophageal cancer, Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas YAP1 tissue; Open Targets ENSG00000137693 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Sudol et al, J. Biol. Chem, 1995, "Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain". Source.
Sources: HGNC HGNC:16262 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P46937 (protein name, function text, keywords and locations (REST API)); CIViC gene YAP1 (3 evidence items, 0 assertions, 2 variants; diseases: Oesophageal Cancer (GraphQL API, CC0)); Open Targets ENSG00000137693 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: breast cancer 0.54 (GraphQL API, CC0))
Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signalling pathway, crucial for organ size control and tumour suppression by restricting proliferation and promoting apoptosis. The Hippo signalling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1. This activation leads to the phosphorylation and inactivation of the YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1/2 prevents its nuclear translocation, thereby regulating the expression of its target genes. The transcriptional regulation of gene expression requires TEAD transcription factors and modulates cell growth, anchorage-independent growth, and induction of epithelial-mesenchymal transition (EMT). Location: Cytoplasm; Nucleus; Cell junction, tight junction; Cell membrane (UniProt). Locus 11q22.1 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Breast, Bronchus, Cerebral cortex, Cervix, Colon, Duodenum.
Medium only: breast cancer, colorectal cancer, endometrial cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
It offers the first credible explanation for why only a minority of small-cell patients get a durable benefit from checkpoint blockade, and it introduces subtype switching, which would mean retesting at relapse rather than typing once.
It is the reality check on the subtype model and it has a direct consequence for treatment: the DLL3-directed medicines are aimed at the neuroendocrine-high subtypes, and the POU2F3 and double-negative tumours will not express the target.
The organising framework for every small-cell lung cancer trial designed since. It is also why the slow progress in the disease is now attributed to treating four diseases as one rather than to the biology being intractable.
Query for this target: (TITLE:"YAP1" OR ABSTRACT:"YAP1" OR TITLE:"Yes1 associated transcriptional regulator" OR ABSTRACT:"Yes1 associated transcriptional regulator" OR TITLE:"Transcriptional coactivator YAP1" OR ABSTRACT:"Transcriptional coactivator YAP1" OR TITLE:"YAP65" OR ABSTRACT:"YAP65" OR TITLE:"YAP-1" OR ABSTRACT:"YAP-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about YAP1, not a curated reading list.
Shares SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization, Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Lineage plasticity & neuroendocrine transformation.
Shares SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization, Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Small-cell lung cancer.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, CIViC, Open Targets Platform.
Shares Hippo-YAP/TAZ, Breast cancer (all types), Open Targets Platform.
Shares SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization, Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Small-cell lung cancer.
Shares Hippo-YAP/TAZ, CIViC, Breast cancer (all types), Open Targets Platform.
Shares Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, Oesophageal cancer, CIViC.
Shares SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization, Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities, Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Lineage plasticity & neuroendocrine transformation.